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HIV infection of CD4+ T helper cells results in a gradual deterioration of immune function and leads to the onset of the 
Acquired Immune Deficiency Syndrome (AIDS).  Current research suggests that HIV infection may be combated with ribozyme 
therapy.  Hammerhead ribozymes are small, catalytic RNAs that can be designed to cleave substrate RNAs at specific 
sequences, and those targeted to HIV-1 mRNAs have been shown to greatly reduce or inhibit viral replication.  The HIV-1 
virion infectivity factor (vif) gene encodes a protein that counteracts an innate, antiretroviral defense mechanism of non-
permissive CD4+
Introduction 
 T helper cells.  This mechanism is mediated by apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like 3G (APOBEC3G), a cellular cytidine deaminase that is encapsulated into assembling virions in the absence of 
vif and is inhibitory during the next round of viral replication.  Vif neutralizes APOBEC3G by reducing its translation and by 
rapid degradation of the native protein.  Vif mRNA, therefore, may be a good target for ribozyme mediated inhibition of HIV-1 
replication.  To test this hypothesis a catalytic hammerhead ribozyme targeted to nucleotide 5113 of the HIV-1 genomic clone 
NL43 (Accession # M19221) was designed and synthesized.  A non-catalytic control, Vif5113∆ was also designed and 
synthesized.  Vif5113 and Vif5113Δ were cloned into the retroviral vector, pSuper.retro.puro (pSRP) to facilitate tissue culture 
studies.  In this study, Vif5113 and Vif113Δ ribozymes were analyzed for their ability to reduce vif expression in an 
intracellular cleavage assay.  These studies, as determined by Western blot analysis, suggested that vif expression was reduced 
in the presence of the catalytic ribozyme Vif5113.  
HIV-1 is a retrovirus that infects CD4+
 The HIV-1 genome encodes nine viral genes from 
which fifteen functional gene products are expressed (8).  One of 
these genes, the virion infectivity factor (vif) encodes a 23 kD 
protein that counteracts an innate, antiretroviral defense 
mechanism of CD4
 T helper cells 
(1;2) resulting in a gradual deterioration of immune function and 
eventually leading to the onset of the Acquired Immune 
Deficiency Syndrome (3-6).  In December 2007, the World 
Health UNAIDS Organization estimated that 33 million people 
worldwide were living with HIV/AIDS.  It was also estimated 
that 14,000 people worldwide become newly infected with the 
Human Immunodeficiency Virus (HIV) every day (7).  
+
APOBEC3G expression is stimulated by certain viral 
proteins such as HIV-1 Vif.  Normally, APOBEC3G is 
encapsulated into progeny virions, where it remains non-
functional until the virion infects its host cell.  Upon infection of 
the host cell and reverse transcription of the viral genome, 
APOBEC3G induces hypermutation from C to U in the minus 
strand of viral DNA resulting in G to A mutations in the positive 
sense DNA strand.  These mutations in the viral genome inhibit 
normal expression of viral genes and render the target cell 
incapable of producing progeny virions and facilitating a 
productive infection (8).   
 T helper cells (9), the primary target of HIV 
(2).  This resistance to HIV infection is due to the expression of 
APOBEC3G (human apolipoprotein B mRNA-editing enzyme 
catalytic polypeptide-like 3G), which acts to inhibit reverse 
transcription of retroviruses (8).  
Vif counteracts this activity by binding APOBEC3G 
and targeting the protein for degradation through the ubiquitin 
pathway (10).  We hypothesized that downregulating vif 
expression in infected cells would reconstitute the normal 
antiviral activity of APOBEC3G.  Previous research suggested 
that HIV infection may be combated with ribozyme therapy (11-
13).  Hammerhead ribozymes are small, catalytic RNAs that can 
be designed to target and cleave substrate RNAs at sequence 
specific sites (14).  These ribozymes cleave mRNAs at the target 
sequence XUX’ where X is A, C, G, or U and X’ is A, C, or U  
(15).  In this report, a hammerhead ribozyme targeted to HIV-1 
vif was designed and cloned into the retroviral vector, 
pSuper.retro.puro (16;17).  This vector was chosen due to its 
ability to express siRNAs from the RNA Polymerase III H1 
promoter, and we hypothesized that it would also efficiently 
express ribozymes.  As a control, a non-catalytic ribozyme 
targeted to the same HIV-1 vif sequence was designed and 
cloned.  These constructs were tested for their antiviral activity in 
a vif inhibition assay.  These results suggested that vif expression 
was reduced in the presence of a hammerhead ribozyme.  
 Materials and Methods 
Cloning  
The HIV-1 NL43 vif sequence (Accession number 
M19921) was analyzed for the presence of potential hammerhead 
cleavage sites (15).  One such sequence, a pGUA was located at 
nucleotide 5113.  This sequence along with its immediate 
flanking sequences were used to generate a hammerhead 
ribozyme according to the Haseloff and Gerlach model (14).  A 
non-catalytic control ribozyme was generated by an A to G 
substitution within the ribozyme catalytic core (12) (Figure 1).  
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Figure 1. Hammerhead ribozyme design.  Vif RNA containing the pGUA 
cleavage site at nucleotide 5113 is shown annealed to the ribozyme 
flanking regions.  An A to G mutation in the catalytic core converted the 
ribozyme to a non-catalytic form. 
The Vif5113 and Vif5113∆ ribozymes were 
synthesized (5’ACA TAT GGT GTT TCT GAT GAG TCC GTG 
AGG ACG A/GAA CTA ATC TTT TCC AT 3’) and cloned into 
the shuttle vector pPCR-Script (Stratagene) as previously 
described (18).  Correct insertion of the ribozyme in the resulting 
plasmids pVif5113 and pVif5113∆ was verified by sequencing.  
To study ribozyme-mediated anti-Vif activity in cell 
culture, each ribozyme was moved into the retroviral vector, 
pSuper.retro.puro (Oligoengine).  For this ribozyme-specific 
primers were designed and synthesized to include HindIII and 
BglII restriction sites: Vif5113BglII Forward (5’ ATT AGA TCT 
ACA TAT GGT GTT TCT GAT GAG 3’) and Vif5113HindIII 
Reverse (5’ ATT AAG CTT ATG GAA AAG ATT AGT TTC G 
3’).  Each ribozyme was amplified using Vent DNA Polymerase 
(New England Biolabs) and re-cloned into pPCR-Script.  The 
BglII/HindIII ribozyme fragments from each of the resulting 
plasmids were gel purified and cloned into the similarly digested 
pSuper.retro.puro vector.  Accurate cloning was verified by 
sequencing and the resulting retroviruses, pSRPVif5113 and 
pSRPVif5113∆, were analyzed for their anti-vif activity. 
 
Cells and Transfection 
293T cells were maintained in Dulbecco’s Modification 
of Eagle’s medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (Atlanta Biologicals) in a humidified 37°C 
incubator with 5% CO2.  All transfections were done using the 
calcium phosphate precipitation method of Berkner and Sharp 
(19).  Twenty-four hours prior to transfection, 1.0 x 106 cells 
were plated into 100 mm dishes.  The following day, the medium 
was replaced and the cells were transfected  with 10 or 15 µg 
plasmid DNA in 125 mM CaCl2, 2X HBS (280 mM NaCl/ 1.5 
mM Na2HPO4
 
/ 50 mM HEPES Buffer (pH 7.05)).  After an 
overnight incubation, the DNA precipitate was removed and 
replaced with fresh medium.  Forty-eight hours after transfection 
cells were assayed for transgene expression.  Transfection 
efficiency was monitored by observation of GFP expression in 
control cells transfected with a GFP-expression plasmid.    
Vif inhibition assay 
To determine the ability of the hammerhead ribozyme 
Vif5113 to inhibit vif expression, a transient inhibition assay was 
employed.  For this, 293T cells were co-transfected with pCMV-
VifFLAG and either pSRP5113 or pSRP5113∆.  HIV-1 vif was 
expressed from pCMV-Vif FLAG, which encodes the HIV-1 
NL43 vif gene fused to the FLAG epitope (20).  pSRP5113 was 
transfected at a 1:1 (ribozyme to vif) or 2:1 (ribozyme to vif) 
plasmid ratio.  The 1:1 ratio mixtures consisted of 5 µg of 
pSRP5113 or pSRP5113∆ and 5 µg of pCMV-VifFLAG, for a 
total of 10 µg DNA.  The 2:1 ratio mixtures consisted of 10 µg of 
either pSRP5113 or pSRP5113∆ and 5 µg of pCMV-VifFLAG, 
for a total of 15 µg DNA.   
 
Protein Isolation 
Total protein was isolated from the transfected cells 
using RIPA buffer containing protease inhibitors (PBS/0 .1 % 
SDS/1 % NP40/0.5 % sodium deoxycholate/1 µg/µL aprotinin/1 
µg/µL leupeptin/1 µg/µL pepstatin/1 µM NaF/0.1 µM NaVO4
Protein concentrations were determined using the 
Bradford assay (BioRad).  Briefly, 5 µL of each protein sample 
was added to a microplate well along with 250 µL of room 
temperature 1X Bradford reagent.  The samples were mixed, 
incubated for five minutes at RT, and read on the microplate 
reader at 595 nm.  Protein concentrations and total protein were 
determined using the standard curve generated from BSA 
standards.   
/ 
0.1 mg/mL PMSF).  Forty-eight hours following transfection, the 
medium was aspirated, and the cells were washed 2X with 4 mL 
ice cold PBS.  One milliliter of ice cold PBS was added to each 
dish, the cells were scraped from the plate and transferred to a 
microcentrifuge tube.  The cells were centrifuged at 14,000 rpm 
for 2 minutes, the supernatant was removed, and the pellet was 
resuspended in 200 µL RIPA buffer.  The lysate was 
homogenized by passing through a 1 mL syringe with a 21 gauge 
needle.  The lysate was incubated on ice for 60 minutes with 
mixing every 10 minutes.  Subsequently, the lysate was spun at 
14,000 rpm for 20 min at 4°C, and the supernatant was 
transferred into a new microcentrifuge tube.  The isolated protein 
was stored at -20°C.  
 
SDS PAGE and Transfer 
Protein samples from transfected 293T cells were 
thawed on ice and 50 µg of each were combined with an equal 
volume of 2X treatment dye (95% formamide/0.025% 
SDS/0.025% bromophenol blue/0.025% xylene cyanol 
FF/0.5 mM EDTA).  For the positive control generated by 
transfecting with pCMV-VifFLAG alone, 28 µg of total protein 
was added due to a smaller yield in this sample.  The samples 
were heated to 100°C for 3 minutes to denature the proteins and 
immediately quenched on ice.  The proteins were separated by 
molecular weight in a 12 % polyacrylamide gel in 1X Tris-
glycine buffer (21).  The gel was run at 8 volts/cm (60 V) until 
the treatment dye reached the resolving gel.  The voltage was 
then increased to 15 volts/cm (105 V) to separate the proteins.  
The separated proteins were transferred using a semi-dry 
apparatus (Owl Scientific) to a PVDF membrane.  Briefly, a 
PVDF membrane was cut to equal the size of the resolving gel 
and activated by soaking in methanol for 3 minutes.  Six pieces of 
similarly sized filter paper were soaked in Towbin buffer (25 mM 
Tris/192 mM glycine/10 % methanol/ 0.1 % SDS).  The gel, 
membrane, and filter paper were stacked according to the 
manufacturer’s protocol, and the proteins were transferred at 
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70mA for 2 hours.  The membrane was immediately incubated in 
Ponceau Stain (0.5 g Ponceau-S in 1 % acetic acid) for 5 minutes 
and subsequently incubated with Ponceau destain (1 % acetic 
acid) until the bands were visible.     
 
Western Blot  
The membrane was blocked in PBS/5% powdered milk 
overnight at 4°C.  The following day, the membrane was washed 
2X with PBS for 2 minutes per wash, and incubated in 10 mL 
PBS containing 20 µg anti-FLAG M2 antibody (Stratagene) at 
room temperature with gentle rocking for one hour.  This was 
followed by two washes with PBS for 2 minutes per wash.  The 
secondary goat anti-mouse HRP conjugate antibody (Chemicon) 
was diluted 1:5000 in blocking solution and added to the 
membrane.  The membrane was incubated with the secondary 
antibody for two hours at room temperature with gentle rocking, 
and then washed 3X with PBS for 5 minutes per wash.  The ECL 
detection reagent (Amersham) was prepared and added to the 
membrane.  The membrane was incubated at room temperature 
for 5 minutes, excess reagent was drained away, and the 
membrane was wrapped in plastic.   The blot was placed in a 
cassette with X-ray film (Kodak) and allowed to expose the film 
overnight.  The film was hand developed using Kodak reagents. 
Results 
The HIV-1 NL43 vif genomic sequence was analyzed 
for the presence of potential hammerhead ribozyme target sites.  
One site, a pGUC located at nucleotide 5113 was used to design 
an anti-vif hammerhead ribozyme.  This ribozyme and its non-
catalytic control (Figure 1) were synthesized and cloned into the 
retroviral vector, pSuper.retro.puro.  Sequencing was used to 
verify the ribozyme sequence in the resulting plasmids: 
pSRP5113 and pSRP5113∆ (Figure 2).  
 
 
Figure 2. The retroviral vector pSRP5113.  An anti-vif ribozyme targeted 
to nucleotide 5113 of the HIV NL43 sequence was cloned into the 
retroviral vector, pSuper.retro.puro.  The resulting vector is shown.  A 
similar vector was constructed that expresses a non-catalytic form of the 
ribozyme, pSRP5113∆. 
The ability of the Vif5113 hammerhead ribozyme to 
reduce expression was analyzed using a vif inhibition assay.  For 
this, two series of co-transfections were carried out in 293T cells 
using either pSRP5113 or pSRP5113∆ and the HIV vif expression 
plasmid, pCMV-VifFLAG.  The first series of co-transfections 
included 5 µg of pSRPVif5113 or pSRP5113∆ and 5 µg of 
pCMV-VifFLAG.  A second series of co-transfections included 
10 µg of either pSRPVif5113 or pSRPVif5113∆ and 5 µg of 
pCMV-VifFLAG.  A 5 µg transfection of a GFP-expressing 
plasmid served as a negative control.  
The intracellular cleavage ability of the anti-vif 
ribozyme was analyzed by Western blot.  Forty-eight hours after 
each transfection series, total protein was obtained from the cells 
and 50 µg of each was separated using a 12% polyacrylamide gel.   
The separated proteins were transferred to a PVDF membrane 
and probed using an anti-FLAG antibody. The resulting blot was 
analyzed to determine the relative levels of vif expression.  A 
band present at 23 kD was assumed to be HIV Vif (Figure 3).   
 
Figure 3.  Analysis of vif expression.  293T cells were transfected as 
follows: Con(-) – GFP; lane 1 – 1:1 pSRPVif5113 to pCMV-VifFLAG; 
lane 2 – 1:1 pSRPVif5113∆ to pCMV-VifFLAG; lance 3 – 2:1 pSRP5113 
to pCMV-VifFLAG; and lane 4 – 2:1 pSRP5113∆ to pCMV-VifFLAG.  
These results indicated that at the 1:1 ratio, the catalytic ribozyme, 
Vif5113 reduced vif expression. 
Transfection of 293T cells with a 1:1 mixture of the 
catalytic ribozyme, pSRP5113 and pCMV-VifFLAG indicated a 
reduction of vif activity (Figure 3, compare lanes 1 and 2).  No 
such decrease in vif expression was observed when the ribozyme 
was transfected at a 2:1 ratio (pSRP5113 to pCMV-VifFLAG).  
In this instance the level of vif expression in cells transfected with 
the catalytic and non-catalytic ribozymes appeared to be the 
same. (Figure 3, compare lanes 3 and 4). This produced a 
confounding result, which has yet to be fully resolved.   
Discussion 
HIV-1 vif encodes a protein that neutralizes an 
inhibitory host defense mechanism mediated by apolipoprotein B 
mRNA-editing enzyme-catalytic polypeptide-like 3G 
(APOBEC3G) (8).  This protein is a cellular cytidine deaminase 
that is encapsulated into assembling virions in the absence of vif 
and is inhibitory during the next round of viral replication.  Vif 
neutralizes APOBEC3G by reducing its translation and by rapid 
degradation of the native protein (10).   
Because Vif inhibits APOBEC3G, its cleavage by 
hammerhead ribozymes may decrease the infectivity of HIV-1 
virions.  To test this hypothesis an anti-Vif ribozyme targeted to 
nucleotide 5113 within the HIV NL43 vif open reading frame and 
its non-catalytic control were cloned into the retroviral vector 
pSuper.retro.puro for tissue culture analysis.  Our preliminary 
analysis suggested that the ribozyme was able to decrease vif 
expression in a transient assay.  This was supported by a series of 
co-transfections using a 1:1 ratio of ribozyme and vif expression 
plasmids.  However, a similar series of co-transfections using a 
2:1 ratio of these plasmids produced conflicting results.  In this 
second transfection series, the samples revealed bands of 
approximate equal intensity suggesting that the ribozyme had no 
effect on vif expression.   
However, after further analysis it was determined that 
there were discrepancies in the total amount of protein added to 
lane 2 (1:1 pSRP5113∆ to pCMV-VifFLAG) and 3 (2:1 
Con(-)         1                2               3              4 
 
 Journal of the South Carolina Academy of Science, [2009], 7(2) 17 
pSRP5113 to pCMV-VifFLAG).  In both cases the amount of 
protein was determined to be approximately 50% less than 
originally calculated.  Notwithstanding, when comparing the 1:1 
catalytic transfection, the data suggest that the ribozyme may be 
inhibiting vif expression (Figure 3, compare lane 1 and 2).  With 
more protein in the Vif5113 sample (lane 1) as compared to the 
Vif5113∆ samples (lane 2), the differences are even greater than 
at first appeared. This also holds true when comparing lane one 
(Vif5113) with the other sample transfected with the non-
catalytic ribozyme (lane 4).  Importantly, approximately equal 
amounts of protein were loaded in these two lanes (1 and 4).  
These data suggest that the ribozyme may be reducing vif 
expression in this cellular model.  However; the relatively equal 
amounts of vif expression observed in lanes 3 and 4 do not 
support this conclusion.  These two samples were obtained from 
cells that contained catalytic and non-catalytic ribozymes 
transfected at a 2:1 ratio.  Therefore, further analyses are required 
to reproduce this data and ascertain the efficiency of ribozyme-
mediated degradation of vif mRNA 
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